WO2000063350A3 - Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis - Google Patents

Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis Download PDF

Info

Publication number
WO2000063350A3
WO2000063350A3 PCT/US2000/010672 US0010672W WO0063350A3 WO 2000063350 A3 WO2000063350 A3 WO 2000063350A3 US 0010672 W US0010672 W US 0010672W WO 0063350 A3 WO0063350 A3 WO 0063350A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
treatment
neurocysticerocosis
prevention
cysteine protease
Prior art date
Application number
PCT/US2000/010672
Other languages
French (fr)
Other versions
WO2000063350A9 (en
WO2000063350A2 (en
Inventor
Salman Baig
Raymond T Damien
Arthur Clinton White
Original Assignee
Univ Georgia Res Found
Baylor College Medicine
Salman Baig
Raymond T Damien
Arthur Clinton White
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia Res Found, Baylor College Medicine, Salman Baig, Raymond T Damien, Arthur Clinton White filed Critical Univ Georgia Res Found
Priority to AU46505/00A priority Critical patent/AU4650500A/en
Priority to MXPA01010541A priority patent/MXPA01010541A/en
Priority to BR0009944-9A priority patent/BR0009944A/en
Publication of WO2000063350A2 publication Critical patent/WO2000063350A2/en
Publication of WO2000063350A3 publication Critical patent/WO2000063350A3/en
Publication of WO2000063350A9 publication Critical patent/WO2000063350A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A Taenia cyst wall cysteine proteinase and inhibitors thereof. Also included are pharmaceutical compositions and vaccines for treatment of Taenia infection; methods of inhibiting the activity of a cyst wall cysteine proteinase, and computer-assisted methods for identifying inhibitors of cyst wall cysteine proteinase activity.
PCT/US2000/010672 1999-04-21 2000-04-20 Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis WO2000063350A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU46505/00A AU4650500A (en) 1999-04-21 2000-04-20 Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis
MXPA01010541A MXPA01010541A (en) 1999-04-21 2000-04-20 Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis.
BR0009944-9A BR0009944A (en) 1999-04-21 2000-04-20 Cysteine protease and inhibitors for the prevention and treatment of neurocysticercosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13033899P 1999-04-21 1999-04-21
US60/130,338 1999-04-21

Publications (3)

Publication Number Publication Date
WO2000063350A2 WO2000063350A2 (en) 2000-10-26
WO2000063350A3 true WO2000063350A3 (en) 2001-02-08
WO2000063350A9 WO2000063350A9 (en) 2002-06-13

Family

ID=22444218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010672 WO2000063350A2 (en) 1999-04-21 2000-04-20 Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis

Country Status (5)

Country Link
CN (1) CN1352682A (en)
AU (1) AU4650500A (en)
BR (1) BR0009944A (en)
MX (1) MXPA01010541A (en)
WO (1) WO2000063350A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535560A (en) * 2001-04-20 2004-11-25 ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション， インク． Active site inactivator
EP2633855A1 (en) 2012-03-01 2013-09-04 Veterinärmedizinische Universität Wien Protease inhibitors for treating Trichomonas gallinae infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010225A1 (en) * 1991-11-12 1993-05-27 The Colorado State University Research Foundation Protease vaccine against heartworm
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US5618542A (en) * 1988-05-12 1997-04-08 Coopers Animal Health Nz Limited Vaccines comprising antigenic polypeptides of Taenia ovis
WO1998046633A1 (en) * 1997-04-11 1998-10-22 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618542A (en) * 1988-05-12 1997-04-08 Coopers Animal Health Nz Limited Vaccines comprising antigenic polypeptides of Taenia ovis
WO1993010225A1 (en) * 1991-11-12 1993-05-27 The Colorado State University Research Foundation Protease vaccine against heartworm
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1998046633A1 (en) * 1997-04-11 1998-10-22 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WHITE ET AL.: "Detection and preliminary characterization of Taenia solium metacestode proteases", JOURNAL OF PARASITOLOGY, vol. 78, no. 2, 1992, pages 281 - 287, XP000965373 *

Also Published As

Publication number Publication date
CN1352682A (en) 2002-06-05
WO2000063350A9 (en) 2002-06-13
MXPA01010541A (en) 2003-08-19
BR0009944A (en) 2002-01-08
WO2000063350A2 (en) 2000-10-26
AU4650500A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
HK1163061A1 (en) Peptidomimetic protease inhibitors and intermediates for their preparation as treatment for hcv infection
WO2002000651A3 (en) Factor xa inhibitors
HUP0300720A3 (en) Serine protease inhibitors, pharmaceutical compositions containing them and their use
ZA200200094B (en) Nitrogen containing heterobicycles as factor xa inhibitors.
AU3511500A (en) Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
ZA200108082B (en) Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth.
EP1273298A3 (en) Ritonavir in combination with an additional HIV protease inhibitor for treating aids
GEP20012415B (en) THF-Containing Sulfonamide Inhibitors of Aspartyl Protease
BR9908280A (en) Phospholipase enzyme inhibitors
HUP0105077A3 (en) Serine protease inhibitors and pharmaceutical compositions containing them
AU3413100A (en) Method and compositions for preventing or reducing hiv infection by use of inhibitors for leucine aminopeptidase
AU6007200A (en) Cysteine protease inhibitors
IL152553A0 (en) Compounds and methods for the treatment and prevention of bacterial infection
WO2001085201A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2002040016A8 (en) Association of calpain inhibitors and reactive oxygen species trapping agents
GB9907571D0 (en) Compounds
AU3719100A (en) Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2002002519A3 (en) THROMBIN OR FACTOR Xa INHIBITORS
WO2000063350A3 (en) Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis
AU2003231865A1 (en) Alpha acyloxyacetamides for kallikrein and urokinase inhibition
AU2003274565A8 (en) Composition for the treatment of nasopharyngeal carcinoma and method of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00806591.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 200108541

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010541

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 10018936

Country of ref document: US

Ref document number: IN/PCT/2001/1455/CHE

Country of ref document: IN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP